Skip to main content

Theravance Biopharma, Inc.

corporate_fare Company Profile

Theravance Biopharma, Inc.

TBPH·NASDAQ·Life Sciences·CIK 0001583107

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing medicines. The company leverages its expertise to develop medicines, including the U.S. Food and Drug Administration (FDA) approved YUPELRI (revefenacin) inhalation solution. YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). On March 3, 2026, the company announced that its ampreloxetine Phase 3 clinical study (CYPRESS), which was in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy, did not meet its primary endpoint in the Orthostatic Hypotension Symptom Assessment composite score. Consequently, the ampreloxetine program is being wound down. A Strategic Review Committee, formed in 2024, is accelerating its review of alternatives to maximize shareholder value, working with Lazard, its independent financial advisor. This review includes evaluating a broad range of value-maximizing and tax-efficient alternatives, such as a potential sale of the company. The company will complete additional analyses of the CYPRESS dataset and Phase 3 program to assess if the data warrants further regulatory discussion.

Theravance Biopharma, Inc. (NASDAQ:TBPH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for TBPH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-18, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 14 rated 8 or above. Recent SEC coverage for TBPH spans 8-K, DEFA14A, DEFM14A, PREM14A.

Recent high-impact activity:

  • Theravance Shareholders Approve $17/Share Zymeworks Merger; Closing Expected Sept 23
  • Lawsuits Seek to Block Theravance's $17/Share Sale to Zymeworks
  • Theravance Discloses Three Merger Lawsuits and Supplemental Proxy Details Ahead of Sept 18 Vote
  • Theravance Discloses CYPRESS Phase 3 Miss and FDA Path Forward for Ampreloxetine
  • CYPRESS Phase 3 Misses Primary Endpoint, but FDA Signals Path Forward for Ampreloxetine

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$107.46M
Net Income
$105.89M
Diluted EPS
$2.06
Op. Cash Flow
$238.54M
Free Cash Flow
$238.5M
Operating Income
-$3.6M
Cash & Equivalents
$167.81M
Debt / Equity
0.00×
Net Margin
98.5%
Shares Outstanding
51.07M sh
Source: 10-K · filed 2026-03-23 · accession 0001104659-26-033077
Browse all tickers starting with T →

No longer listed

TBPH (Theravance Biopharma, Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed TBPH - Latest Insights

TBPH
Sep 18, 2026, 5:16 PM EDT
Filing Type: 8-K
Importance Score:
8
TBPH
Sep 10, 2026, 11:03 AM EDT
Source: Seeking Alpha
Importance Score:
7
TBPH
Sep 10, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
7
TBPH
Aug 25, 2026, 4:54 PM EDT
Filing Type: DEFA14A
Importance Score:
8
TBPH
Aug 25, 2026, 4:52 PM EDT
Filing Type: 8-K
Importance Score:
7
TBPH
Aug 21, 2026, 6:27 AM EDT
Filing Type: DEFM14A
Importance Score:
8
TBPH
Aug 11, 2026, 8:13 AM EDT
Filing Type: PREM14A
Importance Score:
9
TBPH
Aug 10, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
7
TBPH
Aug 10, 2026, 8:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
TBPH
Jul 01, 2026, 7:33 PM EDT
Filing Type: 4
Importance Score:
7
TBPH
Jun 29, 2026, 6:32 AM EDT
Filing Type: DEFA14A
Importance Score:
10
TBPH
Jun 29, 2026, 6:30 AM EDT
Filing Type: 8-K
Importance Score:
9
TBPH
Jun 29, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
TBPH
May 07, 2026, 9:00 AM EDT
Filing Type: 10-Q
Importance Score:
9
TBPH
May 07, 2026, 8:36 AM EDT
Filing Type: 8-K
Importance Score:
8
TBPH
May 07, 2026, 8:33 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
TBPH
Apr 28, 2026, 4:59 PM EDT
Filing Type: DEF 14A
Importance Score:
8
TBPH
Mar 23, 2026, 8:46 AM EDT
Filing Type: 10-K
Importance Score:
9
TBPH
Mar 19, 2026, 8:38 AM EDT
Filing Type: 8-K
Importance Score:
9
TBPH
Mar 03, 2026, 8:46 AM EST
Source: Reuters
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets